In Q2 2026, Foresite Capital held 6 positions worth $290.2M. They initiated 1 new position and exited 10. Their largest holding was PHVS ($165.2M). Portfolio value grew +22.4% versus the prior quarter.
Frequently asked questions
What stocks did Foresite Capital own in Q2 2026?
Foresite Capital held 6 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include PHVS, CYTK, EIKN, RLAY, XENE. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Foresite Capital's portfolio worth in Q2 2026?
Foresite Capital's tracked biotech portfolio was worth $290.2M across 6 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Foresite Capital buy in Q2 2026?
Foresite Capital initiated 1 new position in Q2 2026, including CRNX. They also increased 2 existing positions.
What did Foresite Capital sell in Q2 2026?
Foresite Capital fully exited 10 positions in Q2 2026, including ALEC, LYEL, QSIAW, MAZE, ACRS and 5 more. They also trimmed 0 existing positions.
Is Foresite Capital a biotech fund?
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
Want AI analysis, insider signals, and catalyst overlays for Foresite Capital?
View latest Foresite Capitalportfolio →